Akumin — Q1 2022 Earnings Presentation
14 slides from Akumin's earnings presentation, May 10, 2022
Slide 1: Q1 2022 Results
Akumin Inc. Q1 2022 Results May 2022 Riadh Zine, Chairman & CEO Bill Larkin, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forward-Looking Statements This presentation may contain forward-looking information or forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-looki
Slide 3: Akumin At a Glance
Akumin At a Glance • #2 fixed site radiology provider • #1 mobile radiology provider • #2 provider of MRI services • #1 provider of PET/CT services • #2 provider of radiation therapy services to U.S. hospitals Caring for ~2 million radiology patients per year and treating more than 10,000 cancer pat
Slide 4: Comprehensive Outpatient Solutions Provider to Hospitals and Health Systems
Comprehensive Outpatient Solutions Provider to Hospitals and Health Systems On-Campus Off-Campus Mobile Regional Networks Fixed Sites Fixed Sites • Shared platform, part-time, • Within or adjacent to hospital • Convenient location • Market or regional strategy daily, weekly • Single or multi-modalit
Slide 5: Diverse Payor Mix
Diverse Payor Mix TTM Q1’22 Pro Forma ~95% of the company’s overall Payor Mix1 revenue is derived from (% of Revenue) outpatient procedures • 50% of revenue is received via third party and government payers, and reimbursed at outpatient rates • 50% of revenue is received via health systems and hospi
Slide 6: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities • Diversification of revenue between Service Lines (% of Revenue) 1 Radiology and Oncology Radiology Procedure Mix divisions (% of Revenue) • Akumin provides a full suite of radiology and oncology services with a focus on high-growth and high-value modalities 1 P
Slide 7: Q1 2022 Performance Highlights
Q1 2022 Performance Highlights • Same Store Volumes on a pro forma basis across the platform continued to trend positively: • MRI: +4.9% • PET/CT: +7.1% • Total Radiology Procedures: +1.8% • Total Oncology Patient Starts: +5.3% • Revenue of $186.3M, up 191.2% vs. Q1 2021. • Adjusted EBITDA of $32.0M
Slide 8: Radiology Volume Trends
Radiology Volume Trends • Same Store MRI Volume Growth: +4.9% in Q1 2022 • Same Store PET/CT Volume Growth: +7.1% in Q1 2022 • Same Store Total Procedures Volume Growth: +1.8% in Q1 2022 Same Store Volume Growth1 Total Volumes1 MRI PET/CT Total Procedures 1 Pro forma 12 months contribution of the Ac
Slide 9: Oncology Volume Trends
Oncology Volume Trends • Same Store Patient Start Volume Growth: +5.3% in Q1 2022 • Patient Start Volume has returned to pre-pandemic (2019) levels • Revenue/Patient Start is slightly lower than pre-pandemic (2019) levels Same Store Patient Start Volume Growth1 Total - Patient Starts Volume1 Total -
Slide 10: Segment Financial Performance “As Reported” and “Pro Forma Normalized”
Segment Financial Performance “As Reported” and “Pro Forma Normalized” Q1 2022 “As Reported” TTM as of Q1 2022 “As Reported” ($ in M) RAD ONC Corp Total ($ in M) RAD ONC Corp Total Revenue $ 155.3 $ 30.9 $ - $ 186.3 Revenue $ 465.8 $ 77.6 $ - $ 543.4 % vs PY - Fav(Unfav) 142.9% 191.2% % vs PY TTM -
Slide 11: 2022 Guidance Maintained
2022 Guidance Maintained • Maintaining our full year Revenue and Adjusted EBITDA Guidance • Positive same store volume across the platform and strong new customer acquisition as well as retention • Timing of synergy realization related to integrations and transformative initiatives is now expected w
Slide 12: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation for Growth Akumin’s capital structure is Total Secured Debt $ 910.3 comprised of a diverse set of capital Less: Cash 40.2 providers including traditional banks, Net Secured Debt $ 870.1 bondholders and Stonepeak as debt and equity stakeholders. Adj. EBITDA (1)
Slide 13: Thank you!
Thank you! Riadh Zine, Chairman & CEO Bill Larkin, Chief Financial Officer
Slide 14: Appendix 1: Reconciliation of Net Loss to EBITDA and Adjusted EBITDA
Appendix 1: Reconciliation of Net Loss to EBITDA and Adjusted EBITDA ($ in thousands) Three Months Ended March 31, 2022 2021 Net loss $ (26,432) $ (2,508) Interest expense 28,681 8,368 Income tax expense 563 65 Depreciation and amortization 24,731 4,490 EBITDA 27,543 10,415 Adjustments: Stock-based